MARKET

PCSA

PCSA

Processa Pharmaceuticals Inc
NASDAQ
1.860
+0.020
+1.09%
After Hours: 1.860 0 0.00% 19:30 11/13 EST
OPEN
1.865
PREV CLOSE
1.840
HIGH
1.905
LOW
1.800
VOLUME
18.74K
TURNOVER
--
52 WEEK HIGH
8.88
52 WEEK LOW
1.041
MARKET CAP
5.20M
P/E (TTM)
-0.3223
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PCSA last week (1102-1106)?
Weekly Report · 6d ago
Processa Pharmaceuticals, Inc. Outlines Strategic Direction and Expected Capitalization of 309.3 million As-Converted Shares
NASDAQ · 11/06 02:41
Processa Pharmaceuticals, Inc. Appoints Gregory J. Flesher as Chief Operating Officer and Announces Key Leadership Additions
NASDAQ · 11/04 20:28
Processa Pharmaceuticals names Gregory Flesher COO, adds three executives
TipRanks · 11/04 14:18
Processa Pharmaceuticals Appoints Gregory J. Flesher Operations Chief
Benzinga · 11/04 13:06
*Processa Pharmaceuticals Names Gregory Flesher COO >PCSA
Dow Jones · 11/04 13:02
Weekly Report: what happened at PCSA last week (1026-1030)?
Weekly Report · 11/02 09:43
Processa Pharmaceuticals, Inc. Appoints Dr. Sheila Gujrathi as Executive Chair and Announces FDA Clearance of Phase 2 IND for VT-7208
NASDAQ · 10/29 22:42
More
About PCSA
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (NGC) small molecules. Its oncology pipeline consists of NGC-Cap and NGC-Iri (also identified as PCS6422 and PCS11T, respectively) and two non-oncology drugs (PCS12852 and PCS499). NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil. PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan. PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes. Its pipelines also include VT-7208, a Bruton's tyrosine kinase inhibitor therapy for immune-mediated diseases.

Webull offers Processa Pharmaceuticals Inc stock information, including NASDAQ: PCSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PCSA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PCSA stock methods without spending real money on the virtual paper trading platform.